ECM
NTGN

Endurant Capital Management’s Neon Therapeutics, Inc. Common Stock NTGN Stock Holding History

Endurant Capital Management’s Portfolio NTGN Stock Details NTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-193,052
Closed -$332K – 73
2019
Q3 		$332K Sell
193,052
-272,598
-59% -$829K 0.12% 48
2019
Q2 		$2.21M Buy
465,650
+40,359
+9% +$226K 0.87% 34
2019
Q1 		$2.75M Buy
+425,291
New +$2.23M 1.09% 30

Other funds holding NTGN

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Endurant Capital Management's NTGN Position: Q4 2019 in Review

Endurant Capital Management sold out of Neon Therapeutics, Inc. Common Stock (NTGN) in Q4 2019, closing a stake of 193,052 shares — an estimated $332K sold.

Endurant Capital Management first reported a position in NTGN in Q1 2019 and held it in 3 quarters. The position peaked at $2.75M in Q1 2019. 46 funds tracked by Wall St. Rank hold NTGN as of Q4 2019.

  • Endurant Capital Management reported no remaining Neon Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Endurant Capital Management sold 193,052 Neon Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $332K.
  • Endurant Capital Management first reported a position in Neon Therapeutics, Inc. Common Stock in Q1 2019 and held it in 3 quarters.
  • Endurant Capital Management's Neon Therapeutics, Inc. Common Stock position peaked at $2.75M in Q1 2019.
  • 46 funds tracked by Wall St. Rank held Neon Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Endurant Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.